References
- Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979: 63(11–12): 1727–33
- De Vita VT Jr. Hellman H, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott. 1982
- Li MC, Hertz R, Spencer DB. Effect of methotrexate upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956: 93: 361–6
- Burkitt DP. The trail to a virus. In: Giggs PM. DeThe G, Payne LN, eds. Oncogenesis and herpes viruses. Lyon. France: International Agency for Research in Cancer. 1972: 345–8
- Ziegler JL. Management of Burkitt's lymphoma: an update. Cancer Treat Rev 1979: 6(2): 95–105
- De Vita VT Jr. Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970: 73: 881–95
- De Vita VT Jr. Simon RM, Hubbard SM. et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer institute. Ann Intern Med 1980: 92(5): 587–95
- Schein PS, De Vita VT Jr, Hubbard S, et al. Bleomycin. adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976: 85(4): 417–22
- Samson MK, Fisher R, Stephens RL, et al. Vinblastine, bleomycin and cis-diamminedichloroplatinum in disseminated testicular cancer: response to treatment and prognostic correlations. A Southwest Oncology Group Study. Eur J Cancer 1980: 16(10): 1359–66
- Livingston RB, Stephens RL, Bonnet JD, et al. Long-term survival and toxicity in small cell lung cancer. Am J Med 1984: 77(3): 415–7